Last $3.85 USD
Change Today 0.00 / 0.00%
Volume 264.4K
BCLI On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

brainstorm cell therapeutics (BCLI) Key Developments

Brainstorm Cell Therapeutics Inc. to Release Final Results of Phase 2a Trial of NurOwn in ALS

BrainStorm Cell Therapeutics Inc. announced that it will release the final results from its phase 2a clinical trial of NurOwn in amytrophic lateral sclerosis (ALS). This single-arm dose-escalation trial, conducted at Hadassah Medical Center in Jerusalem, enrolled 14 ALS patients, all of whom received a single administration NurOwn through both intrathecal and intramuscular injection. The study assessed both the safety and the efficacy of three ascending doses of NurOwn. Subjects in this study underwent a three month run-in period to establish a baseline rate of disease progression, during which bone marrow-derived mesenchymal stem cells were isolated, expanded and differentiated using BrainStorm's proprietary technology that induces expression of neurotrophic factors.

Brainstorm Cell Therapeutics Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended Sept. 30, 2014

Brainstorm Cell Therapeutics Inc. announced unaudited earnings results for the third quarter and nine months ended Sept. 30, 2014. For the quarter, the company reported operating loss of $2,419,000 against $1,081,000 a year ago. Net loss in the third quarter 2014 was $2.4 million, or $0.16 per common share, as compared to a net loss of $1.1 million, or $0.10 per common share, in the third quarter of 2013. For the nine months, the company reported operating loss of $6,514,000 against $3,663,000 a year ago. For the first nine months of 2014, net loss was $6.5 million, or $0.50 per common share, compared to a net loss of $3.7 million, or $0.36 per common share, for the same period in 2013.

Brainstorm Cell Therapeutics Inc. to Report Q3, 2014 Results on Nov 13, 2014

Brainstorm Cell Therapeutics Inc. announced that they will report Q3, 2014 results at 9:00 AM, Eastern Standard Time on Nov 13, 2014

Brainstorm Cell Therapeutics Inc., Q3 2014 Earnings Call, Nov 13, 2014

Brainstorm Cell Therapeutics Inc., Q3 2014 Earnings Call, Nov 13, 2014

Brainstorm Cell Therapeutics Inc.(NasdaqCM:BCLI) added to NASDAQ Composite Index

Brainstorm Cell Therapeutics Inc. will be added to the NASDAQ Composite Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCLI:US $3.85 USD 0.00

BCLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BCLI.
View Industry Companies
 

Industry Analysis

BCLI

Industry Average

Valuation BCLI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRAINSTORM CELL THERAPEUTICS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.